ClinicalTrials.gg
CompletedNCT01718509Updated Jul 16, 2021Results posted

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

A Phase 3 interventional study of SPD489 (Lisdexamfetamine dimesylate) and Placebo in Binge Eating Disorder, sponsored by Shire. Completed at 48 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Enrollment
9th of 112
390 · median 67
Started
2012
with 2 others
Phase 3
15 of 122
2 open now
Registered
31st of 122
by date
Lead sponsor
5 of 122
Shire

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 9th largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2012, is one of 15 in phase 3, and was the 31st registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by clinical interview based on subject diary

Read the detailed description

Not Required

03

Conditions studied

  • Binge Eating Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subject cannot be enrolled in the study before all of the following inclusion criteria (including test results) are met:

  1. Subject is between 18-55 years of age.
  2. Subject meets the following Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of BED:
  3. Subject has a BED diagnosis.
  4. Subject's BED is of at least moderate severity with subjects reporting at least 3 binge eating days per week.
  5. Female subjects must have a negative serum B-HCG pregnancy test and a negative urine pregnancy test and agree to comply with any applicable requirements.

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from the study if any of the following exclusion criteria are met:

  1. Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
  2. Subject is receiving psychotherapy (eg, supportive psychotherapy, cognitive behavior therapy, interpersonal therapy) or weight loss support (eg, Weight Watchers) for BED.
  3. Subject has used psychostimulants to facilitate fasting or dieting as a part of their BED.
  4. Subject has a lifetime history of psychosis, mania, hypomania, dementia, or ADHD.
  5. Subject is considered a suicide risk, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation.
  6. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
  7. Subject has a history of moderate or severe hypertension.
  8. Subject is female and pregnant or nursing.
  9. Subject has had bariatric surgery, lap bands, duodenal stents, or other procedures for weight loss.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    SPD489 (Lisdexamfetamine dimesylate)

    Drug: SPD489 (Lisdexamfetamine dimesylate)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 50 or 70 mg administered orally, once-daily for up to 12 weeks

    Also known as: Vyvanse, Venvanse, LDX

  • DrugPlacebo

    Administered once-daily, orally, for up to 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Number of Binge Days Per Week at Visit 8 Which Spans Weeks 11/12

    Binge days defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on subject binge diary.

    Time frame: Baseline and Visit 8 Which Spans Weeks 11/12

Secondary outcomes

  1. Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Up to 12 weeks

  2. Percent of Participants With a 4-Week Cessation From Binge Eating

    4-week cessation from binge eating is defined as no binge eating episodes for 28 consecutive days prior to the last study visit.

    Time frame: Up to 12 weeks

  3. Percent Change From Baseline in Body Weight (kg) at Week 12

    Time frame: Baseline and week 12

  4. Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12

    The Y-BOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. Reduction in total score indicates improvement.

    Time frame: Baseline and week 12

  5. Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks

    Time frame: Baseline and up to 12 weeks

  6. Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks

    Time frame: Baseline and up to 12 weeks

  7. Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks

    Time frame: Baseline and up to 12 weeks

  8. Binge Eating Response

    Response is based on the reduction in the number of binge eating episodes. Responses were categorized as follows: -1-week Cessation = 100% reduction in binge episodes during the preceding 7 days -Marked Reduction = 99% to 75% reduction during the time since the previous visit -Moderate Reduction = 74% to 50% reduction during the time since the previous visit -Negative to Minimal Reduction = \<50% reduction during the time since the previous visit

    Time frame: Up to 12 weeks

  9. Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 Which Spans Weeks 11/12

    Time frame: Baseline and Visit 8 Which Spans Weeks 11/12

  10. Change From Baseline in Eating Inventory Scores at Week 12

    There are 36 true/false items, 14 items on a 4-point Likert scale (1=eat rarely to 4=always), and 1 item on a 6-point Likert scale (1=eat whatever you want to 6=constantly limiting food intake). Cognitive Restraint score ranges from 0-21. Hunger score ranges from 0-14. Disinhibition score ranges from 0-16. Higher scores denote higher levels of restrained eating, disinhibited eating and predisposition to hunger.

    Time frame: Baseline and week 12

  11. Change From Baseline in Binge Eating Scale (BES) Score at Week 12

    The BES is a self-reported questionnaire containing 16 items designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. Each item is assessed based on 1 of 4 responses, with 1 denoting that a subject has greater control over eating behavior and 4 denoting that a subject had less control over eating behavior. A total score (sum of the 16 items) may range from 16-64. A lower score indicates greater control over eating behavior.

    Time frame: Baseline and week 12

  12. Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Up to 12 Weeks

    The FrSBe is a 46-item self-rating scale designed to measure the neurobehavioral traits associated with the 3 primary regions of the prefrontal cortex. Subjects were asked to indicate the frequency with which they have engaged in certain behaviors using a rating scale from "1" (almost never) to "5" (almost always). Summary scores were calculated and converted to t-score. A decrease from baseline in FrSBe total score represents improvement.

    Time frame: Baseline and up to 12 weeks

  13. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Mobility

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Time frame: Up to 12 weeks

  14. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Self-Care

    Time frame: Up to 12 weeks

  15. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Usual Activities

    Time frame: Up to 12 weeks

  16. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Pain/Discomfort

    Time frame: Up to 12 weeks

  17. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Anxiety/Depression

    Time frame: Up to 12 weeks

  18. Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

    Time frame: Up to 12 weeks

  19. Change in Amphetamine Cessation Symptom Assessment (ACSA) Total Score From Baseline to Week 12.

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity. Calculated as Baseline (Day 0) - Week 12 ACSA scores.

    Time frame: Baseline and Week 12

07

Results

Posted Aug 21, 2014

Participant flow

Participant flow — Overall Study
MilestonePLACEBOSPD489
Started195195
Completed147147
Not completed4848
Withdrew: Lost to follow-up1815
Withdrew: Withdrawal by subject713
Withdrew: Adverse event57
Withdrew: Other1311
Withdrew: Protocol violation42
Withdrew: Lack of efficacy10

Outcome measures

PrimaryChange From Baseline in the Number of Binge Days Per Week at Visit 8 Which Spans Weeks 11/12

Binge days defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on subject binge diary.

Time frame:
Baseline and Visit 8 Which Spans Weeks 11/12
Reported as:
Least squares mean · Binge days per week
Change From Baseline in the Number of Binge Days Per Week at Visit 8 Which Spans Weeks 11/12
Binge days per weekPLACEBOSPD489
Change From Baseline in the Number of Binge Days Per Week at Visit 8 Which Spans Weeks 11/12-2.26 ± 0.137-3.92 ± 0.135
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 · Least squares mean difference: -1.66 · 95% CI -2.04 to -1.28
SecondaryPercent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
percentage of participantsPLACEBOSPD489
Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores42.9 (35.5 to 50.2)86.2 (81.1 to 91.3)
Statistical analysis
  • PLACEBO vs SPD489 · Chi-squared · p = <0.001
SecondaryPercent of Participants With a 4-Week Cessation From Binge Eating

4-week cessation from binge eating is defined as no binge eating episodes for 28 consecutive days prior to the last study visit.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percent of Participants With a 4-Week Cessation From Binge Eating
percentage of participantsPLACEBOSPD489
Percent of Participants With a 4-Week Cessation From Binge Eating13.1 (8.1 to 18.0)36.2 (29.1 to 43.3)
Statistical analysis
  • PLACEBO vs SPD489 · Chi-squared · p = <0.001
SecondaryPercent Change From Baseline in Body Weight (kg) at Week 12
Time frame:
Baseline and week 12
Reported as:
Least squares mean · percentage change
Percent Change From Baseline in Body Weight (kg) at Week 12
percentage changePLACEBOSPD489
Percent Change From Baseline in Body Weight (kg) at Week 12-0.15 ± 0.353-5.57 ± 0.350
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 · Least squares mean difference: -5.41 · 95% CI -6.39 to -4.44
SecondaryChange From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12

The Y-BOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. Reduction in total score indicates improvement.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12
units on a scalePLACEBOSPD489
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12-7.42 ± 0.571-15.36 ± 0.563
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 · Least squares mean difference: -7.94 · 95% CI -9.51 to -6.36
SecondaryChange From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks
Time frame:
Baseline and up to 12 weeks
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks
mmol/LPLACEBOSPD489
Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks0.062 ± 0.0453-0.133 ± 0.0449
Statistical analysis
  • PLACEBO vs SPD489 · ANCOVA · p = 0.002 · Least squares mean difference: -0.196 · 95% CI -0.321 to -0.070
SecondaryChange From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks
Time frame:
Baseline and up to 12 weeks
Reported as:
Least squares mean · mmol/L
Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks
mmol/LPLACEBOSPD489
Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks-0.126 ± 0.0460-0.204 ± 0.0456
Statistical analysis
  • PLACEBO vs SPD489 · ANCOVA · p = 0.234 · Least squares mean difference: -0.077 · 95% CI -0.205 to 0.050
SecondaryChange From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks
Time frame:
Baseline and up to 12 weeks
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks
PercentPLACEBOSPD489
Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks-0.02 ± 0.0170.01 ± 0.017
Statistical analysis
  • PLACEBO vs SPD489 · ANCOVA · p = 0.185 · Least squares mean difference: 0.03 · 95% CI -0.02 to 0.08
SecondaryBinge Eating Response

Response is based on the reduction in the number of binge eating episodes. Responses were categorized as follows: -1-week Cessation = 100% reduction in binge episodes during the preceding 7 days -Marked Reduction = 99% to 75% reduction during the time since the previous visit -Moderate Reduction = 74% to 50% reduction during the time since the previous visit -Negative to Minimal Reduction = \<50% reduction during the time since the previous visit

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Binge Eating Response
percentage of participantsPLACEBOSPD489
1-week cessation23.955.9
Marked reduction13.422.8
Moderate reduction19.716.6
Negative to minimal reduction43.04.8
Statistical analysis
  • PLACEBO vs SPD489 · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.)
SecondaryChange From Baseline in the Number of Binge Episodes Per Week at Visit 8 Which Spans Weeks 11/12
Time frame:
Baseline and Visit 8 Which Spans Weeks 11/12
Reported as:
Least squares mean · Binge episodes per week
Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 Which Spans Weeks 11/12
Binge episodes per weekPLACEBOSPD489
Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 Which Spans Weeks 11/12-3.31 ± 0.194-5.54 ± 0.193
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -2.23 · 95% CI -2.77 to -1.69
SecondaryChange From Baseline in Eating Inventory Scores at Week 12

There are 36 true/false items, 14 items on a 4-point Likert scale (1=eat rarely to 4=always), and 1 item on a 6-point Likert scale (1=eat whatever you want to 6=constantly limiting food intake). Cognitive Restraint score ranges from 0-21. Hunger score ranges from 0-14. Disinhibition score ranges from 0-16. Higher scores denote higher levels of restrained eating, disinhibited eating and predisposition to hunger.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Eating Inventory Scores at Week 12
units on a scalePLACEBOSPD489
Cognitive Restraint of Eating2.44 ± 0.3523.71 ± 0.347
Disinhibition of Eating-2.01 ± 0.305-5.61 ± 0.300
Perceived Hunger-1.93 ± 0.318-6.14 ± 0.313
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = 0.011 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: 1.27 · 95% CI 0.29 to 2.24
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -3.60 · 95% CI -4.44 to -2.76
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -4.21 · 95% CI -5.09 to -3.33
SecondaryChange From Baseline in Binge Eating Scale (BES) Score at Week 12

The BES is a self-reported questionnaire containing 16 items designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. Each item is assessed based on 1 of 4 responses, with 1 denoting that a subject has greater control over eating behavior and 4 denoting that a subject had less control over eating behavior. A total score (sum of the 16 items) may range from 16-64. A lower score indicates greater control over eating behavior.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Binge Eating Scale (BES) Score at Week 12
units on a scalePLACEBOSPD489
Change From Baseline in Binge Eating Scale (BES) Score at Week 12-8.24 ± 0.781-17.52 ± 0.771
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -9.28 · 95% CI -11.44 to -7.12
SecondaryChange From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Up to 12 Weeks

The FrSBe is a 46-item self-rating scale designed to measure the neurobehavioral traits associated with the 3 primary regions of the prefrontal cortex. Subjects were asked to indicate the frequency with which they have engaged in certain behaviors using a rating scale from "1" (almost never) to "5" (almost always). Summary scores were calculated and converted to t-score. A decrease from baseline in FrSBe total score represents improvement.

Time frame:
Baseline and up to 12 weeks
Reported as:
Least squares mean · t-scores
Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Up to 12 Weeks
t-scoresPLACEBOSPD489
Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Up to 12 Weeks-3.09 ± 0.655-4.05 ± 0.644
Statistical analysis
  • PLACEBO vs SPD489 · ANCOVA · p = 0.298 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -0.96 · 95% CI -2.77 to 0.85
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Mobility

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Mobility
percentage of participantsPLACEBOSPD489
No problems in walking about86.991.7
Slight problems in walking about8.97.1
Moderate problems walking about3.00.6
Severe problems walking about1.20.6
Unable to walk about00
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Self-Care
Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Self-Care
percentage of participantsPLACEBOSPD489
No problems washing or dressing97.097.0
Slight problems washing or dressing2.43.0
Moderate problems washing or dressing0.60
Severe problems washing or dressing00
Unable to wash or dress00
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Usual Activities
Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Usual Activities
percentage of participantsPLACEBOSPD489
No problems doing usual activities82.189.9
Slight problems dosin usual activities14.38.3
Moderate problems doing usual activities3.01.2
Severe problems doing usual activities0.60.6
Unable to do usual activities00
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Pain/Discomfort
Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Pain/Discomfort
percentage of participantsPLACEBOSPD489
No pain or discomfort75.676.3
Slight pain or discomfort18.520.1
Moderate pain or discomfort3.03.0
Severe pain or discomfort3.00
Extreme pain or discomfort00.6
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Anxiety/Depression
Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Anxiety/Depression
percentage of participantsPLACEBOSPD489
Not anxious or depressed69.676.3
Slightly anxious or depressed23.220.7
Moderately anxious or depressed4.82.4
Severely anxious or depressed1.20
Extremely anxious or depressed1.20.6
SecondaryColumbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

Time frame:
Up to 12 weeks
Reported as:
Number · participants
Columbia-Suicide Severity Rating Scale (C-SSRS)
participantsPLACEBOSPD489
Suicidal ideation00
Suicidal behavior00
SecondaryChange in Amphetamine Cessation Symptom Assessment (ACSA) Total Score From Baseline to Week 12.

ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity. Calculated as Baseline (Day 0) - Week 12 ACSA scores.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change in Amphetamine Cessation Symptom Assessment (ACSA) Total Score From Baseline to Week 12.
units on a scalePLACEBOSPD489
Change in Amphetamine Cessation Symptom Assessment (ACSA) Total Score From Baseline to Week 12.7.0 ± 7.694.6 ± 5.83

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PLACEBO—2/185 (1.1%)43/185 (23.2%)
SPD489—1/181 (0.6%)100/181 (55.2%)
Most frequent serious events
Most frequent serious events
EventPLACEBOSPD489
Lumbar vertebral fractureInjury, poisoning and procedural complications0/1851/181
Fibula fractureInjury, poisoning and procedural complications1/1850/181
SyncopeNervous system disorders1/1850/181
AgitationPsychiatric disorders1/1850/181
AnxietyPsychiatric disorders1/1850/181
Most frequent other events
Most frequent other events
EventPLACEBOSPD489
Dry mouthGastrointestinal disorders11/18560/181
HeadacheNervous system disorders16/18532/181
InsomniaPsychiatric disorders6/18519/181
FatigueGeneral disorders9/18517/181
NauseaGastrointestinal disorders8/18516/181
DiarrhoeaGastrointestinal disorders3/18511/181
Decreased appetiteMetabolism and nutrition disorders3/18511/181
ConstipationGastrointestinal disorders1/18510/181
Feeling jitteryGeneral disorders0/18510/181

Baseline characteristics

The Safety Analysis Set defined as all randomized subjects who took at least 1 dose of investigational product and had at least 1 post-baseline safety assessment. 11 subjects from Site 015, 12 subjects had not been treated, and 1 subject had been treated but did not have any safety follow-up assessments were excluded from the Safety Analysis Set.

Age, Continuous
Age, Continuous(Years)PLACEBOSPD489Total
Mean38.7 ± 10.0137.1 ± 10.0037.9 ± 10.02
Age, Customized
Age, Customized(Participants)PLACEBOSPD489Total
< 40 years90108198
>= 40 years9573168
Sex: Female, Male
Sex: Female, Male(Participants)PLACEBOSPD489Total
Female153159312
Male322254
Region of Enrollment
Region of Enrollment(Participants)PLACEBOSPD489Total
GERMANY91120
UNITED STATES176170346
08

Study locations

48 sites
  • Radiant Research, Inc.
    Tucson, Arizona 85710, United States
  • Southern California Research, LLC
    Beverly Hills, California 90210, United States
  • Scripps Clinical Research Services
    La Jolla, California 92037, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Excel Research, Inc.
    Oceanside, California 92056, United States
  • PCSD - Feighner Research
    San Diego, California 92108, United States
  • Radiant Research, Inc.
    Denver, Colorado 80239, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34201, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30342, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • American Medical Research
    Oak Brook, Illinois 60523, United States
  • Deaconess Clinic Gateway Health Center
    Newburgh, Indiana 47630, United States
  • Clinical Trials Technology, Inc.
    Prairie Village, Kansas 66206, United States
  • Louisiana Research Associates, Inc.
    New Orleans, Louisiana 70114, United States
  • Potomac Grove Clinical Research Center
    Gaithersburg, Maryland 20877, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Activmed Practices and Research
    Haverhill, Massachusetts 01830, United States
  • Adams Clinical Trials, LLC
    Watertown, Massachusetts 02472, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • UMN Medical School, Dept of Psychiatry
    Minneapolis, Minnesota 55454, United States
  • Scientella, LLA
    Saint Louis, Missouri 63141, United States
  • Robert Lynn Horne, MD, LTD
    Las Vegas, Nevada 89102, United States
  • Global Medical Inst LLC; Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Bioscience Research, LLC
    Mount Kisco, New York 10549, United States
  • CNS Clinica at the Brain Resource Center
    New York, New York 10023, United States
  • Radiant Research, Inc.
    Akron, Ohio 44311, United States
  • Patient Priority Clinical Sites, LLC
    Cincinnati, Ohio 45215, United States
  • The Craig and Frances Lindner Center of Hope
    Mason, Ohio 45040, United States
  • Clinical Trials of America, Inc.
    Eugene, Oregon 97401, United States
  • Sunstone Medical Research, LLC
    Medford, Oregon 97504, United States
  • Oregon Center for Clinical Investigators (OCCI, Inc)
    Portland, Oregon 97210, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • CRI Lifetree
    Philadelphia, Pennsylvania 19139, United States
  • Omega Medical Reserach
    Warwick, Rhode Island 02886, United States
  • Radiant Research, Inc.
    Greer, South Carolina 29650, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Psychiatric Medical Associates
    Plano, Texas 75093, United States
  • Radiant Research, Inc.
    San Antonio, Texas 78229, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • NeuroScience, Inc.
    Herndon, Virginia 20170, United States
  • Summit Research Network (Seattle), LLC
    Seattle, Washington 98104, United States
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • Klinische Forschung Berlin Buch GmbH
    Berlin, 13125, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
09

References and documents

Publications

  • McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016 Apr;41(5):1251-60. doi: 10.1038/npp.2015.275. Epub 2015 Sep 9. PubMed 26346638 ↗
  • Robertson B, Wu J, Fant RV, Schnoll SH, McElroy SL. Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder. Prim Care Companion CNS Disord. 2020 Mar 26;22(2):19m02540. doi: 10.4088/PCC.19m02540. PubMed 32237290 ↗
  • Kornstein SG, Bliss C, Kando J, Madhoo M. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age. J Clin Psychiatry. 2019 Feb 26;80(2):18m12378. doi: 10.4088/JCP.18m12378. PubMed 30817099 ↗
  • Sheehan DV, Gasior M, McElroy SL, Radewonuk J, Herman BK, Hudson J. Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials. Innov Clin Neurosci. 2018 Jun 1;15(5-6):22-29. PubMed 30013816 ↗
  • Citrome L, Kando JC, Bliss C. Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies. Neuropsychiatr Dis Treat. 2018 Feb 15;14:537-546. doi: 10.2147/NDT.S158395. eCollection 2018. PubMed 29497297 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Sep 2013, 9 months.

Results were first posted in Aug 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2012
First posted
Oct 31, 2012
StartActual
Nov 26, 2012
Primary completionActual
Sep 20, 2013
CompletionActual
Sep 20, 2013
Results first posted
Aug 21, 2014
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01718509
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Oct 31, 2012
Start date
Nov 26, 2012
Primary completion
Sep 20, 2013
Completion
Sep 20, 2013
Results posted
Aug 21, 2014
Last update
Jul 16, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion